1034 related articles for article (PubMed ID: 19398460)
1. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
2. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
3. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
4. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
8. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
10. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
12. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
Roberts JA; Boots R; Rickard CM; Thomas P; Quinn J; Roberts DM; Richards B; Lipman J
J Antimicrob Chemother; 2007 Feb; 59(2):285-91. PubMed ID: 17135183
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
16. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
17. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
